A phase II study of palonosetron to prevent nausea and vomiting induced by CHOP therapy in malignant lymphoma cancer patients.
Phase 2
Recruiting
- Conditions
- malignant lymphoma cancer.
- Registration Number
- JPRN-UMIN000008932
- Lead Sponsor
- Hematology, Department of Medicine Kitasato University, School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1) With other sever diseases 2) Clinical suspicion or history of metastasis to brain or meninges 3) Patients who need anticonvulsants therapy 4) Ascites and/or pleural effusion to need treatment 5) Pyloric stenosis and/or intestinal obstruction 6) Vomiting, or grade 2 or higher nausea according to CTCAE ver4.0 7) History of drug allergy 8) Pregnant or lactating women or women of childbearing potential, and no birth-control 9) Patient who doesn't have ability or intention that cooperates for procedure of the study 10) Not appropriate for the study at the physician's assessment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method